HRP20090523T1 - Novi piridinilaminoalkilen i piridiniloksialkilen ciklopropanamini, postupak njihove priprave i farmaceutski pripravci koji ih sadrže - Google Patents
Novi piridinilaminoalkilen i piridiniloksialkilen ciklopropanamini, postupak njihove priprave i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20090523T1 HRP20090523T1 HR20090523T HRP20090523T HRP20090523T1 HR P20090523 T1 HRP20090523 T1 HR P20090523T1 HR 20090523 T HR20090523 T HR 20090523T HR P20090523 T HRP20090523 T HR P20090523T HR P20090523 T1 HRP20090523 T1 HR P20090523T1
- Authority
- HR
- Croatia
- Prior art keywords
- straight
- branched
- formula
- compounds
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 33
- 125000000217 alkyl group Chemical group 0.000 claims abstract 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 8
- 125000004385 trihaloalkyl group Chemical group 0.000 claims abstract 7
- 125000002252 acyl group Chemical group 0.000 claims abstract 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 6
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000010290 biphenyl Nutrition 0.000 claims abstract 2
- 239000004305 biphenyl Substances 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000005046 dihydronaphthyl group Chemical group 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims abstract 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- UDYAQGAZMQKTNQ-UHFFFAOYSA-N nitro N-(sulfanylidenemethylidene)carbamate Chemical compound [O-][N+](=O)OC(=O)N=C=S UDYAQGAZMQKTNQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 239000011593 sulfur Substances 0.000 claims abstract 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- UXHRXHNTYNSZSJ-UHFFFAOYSA-N 4-[2-chloro-5-[[1-(methylamino)cyclopropyl]methoxy]pyridin-3-yl]benzamide;hydrochloride Chemical compound Cl.C=1N=C(Cl)C(C=2C=CC(=CC=2)C(N)=O)=CC=1OCC1(NC)CC1 UXHRXHNTYNSZSJ-UHFFFAOYSA-N 0.000 claims 1
- DBVZPNFZEDEAMO-UHFFFAOYSA-N 4-[2-chloro-5-[[1-(methylamino)cyclopropyl]methoxy]pyridin-3-yl]benzoic acid;hydrochloride Chemical compound Cl.C=1N=C(Cl)C(C=2C=CC(=CC=2)C(O)=O)=CC=1OCC1(NC)CC1 DBVZPNFZEDEAMO-UHFFFAOYSA-N 0.000 claims 1
- SYTMIKZYAVIQFG-UHFFFAOYSA-N 5-(4-aminophenyl)-6-methyl-n-[[1-(methylamino)cyclopropyl]methyl]pyridin-3-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=1N=C(C)C(C=2C=CC(N)=CC=2)=CC=1NCC1(NC)CC1 SYTMIKZYAVIQFG-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- QMPVMUYCUPGVOZ-UHFFFAOYSA-N [1-[(6-chloro-5-pyridin-4-ylpyridin-3-yl)oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C=1N=C(Cl)C(C=2C=CN=CC=2)=CC=1OCC1(CN)CC1 QMPVMUYCUPGVOZ-UHFFFAOYSA-N 0.000 claims 1
- OZSPIIHMEDAPCW-UHFFFAOYSA-N [1-[[5,6-bis(4-chlorophenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C=1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC(Cl)=CC=2)=CC=1OCC1(CN)CC1 OZSPIIHMEDAPCW-UHFFFAOYSA-N 0.000 claims 1
- MANFXJFZOLAYOE-UHFFFAOYSA-N [1-[[5-(3-methoxyphenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC(C=2C=C(OCC3(CN)CC3)C=NC=2)=C1 MANFXJFZOLAYOE-UHFFFAOYSA-N 0.000 claims 1
- AXMVUGKLWZGGAV-UHFFFAOYSA-N [1-[[5-(4-chlorophenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;hydrochloride Chemical compound Cl.C=1N=CC(C=2C=CC(Cl)=CC=2)=CC=1OCC1(CN)CC1 AXMVUGKLWZGGAV-UHFFFAOYSA-N 0.000 claims 1
- JBGCTFVZFISAGP-UHFFFAOYSA-N [1-[[5-(4-methoxyphenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C1=CN=CC(OCC2(CN)CC2)=C1 JBGCTFVZFISAGP-UHFFFAOYSA-N 0.000 claims 1
- XWAFLFUZWVEZCD-UHFFFAOYSA-N [1-[[6-chloro-5-(3,5-dichlorophenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;hydrochloride Chemical compound Cl.C=1N=C(Cl)C(C=2C=C(Cl)C=C(Cl)C=2)=CC=1OCC1(CN)CC1 XWAFLFUZWVEZCD-UHFFFAOYSA-N 0.000 claims 1
- MDKRFPVVOMETSO-UHFFFAOYSA-N [1-[[6-chloro-5-(3-methoxyphenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC(C=2C(=NC=C(OCC3(CN)CC3)C=2)Cl)=C1 MDKRFPVVOMETSO-UHFFFAOYSA-N 0.000 claims 1
- OTTXJHOVAGSDQU-UHFFFAOYSA-N [1-[[6-chloro-5-(4-fluorophenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;hydrochloride Chemical compound Cl.C=1N=C(Cl)C(C=2C=CC(F)=CC=2)=CC=1OCC1(CN)CC1 OTTXJHOVAGSDQU-UHFFFAOYSA-N 0.000 claims 1
- MBCCTXVXCIJSRZ-UHFFFAOYSA-N [1-[[6-chloro-5-(4-methylsulfanylphenyl)pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1=CC(SC)=CC=C1C1=CC(OCC2(CN)CC2)=CN=C1Cl MBCCTXVXCIJSRZ-UHFFFAOYSA-N 0.000 claims 1
- UVMSLCGNBJXMRX-UHFFFAOYSA-N [1-[[6-chloro-5-[4-(2h-tetrazol-5-yl)phenyl]pyridin-3-yl]oxymethyl]cyclopropyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C=1N=C(Cl)C(C=2C=CC(=CC=2)C2=NNN=N2)=CC=1OCC1(CN)CC1 UVMSLCGNBJXMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- WJXNZPBALGUCOX-UHFFFAOYSA-N ethyl 4-[2-chloro-5-[[1-(methylamino)cyclopropyl]methoxy]pyridin-3-yl]benzoate;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=O)OCC)=CC=C1C1=CC(OCC2(CC2)NC)=CN=C1Cl WJXNZPBALGUCOX-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- VXESQMWLQKRDSH-UHFFFAOYSA-N n-[3-[2-chloro-5-[[1-(methylamino)cyclopropyl]methoxy]pyridin-3-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C=1N=C(Cl)C(C=2C=C(NC(C)=O)C=CC=2)=CC=1OCC1(NC)CC1 VXESQMWLQKRDSH-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600784A FR2896800B1 (fr) | 2006-01-30 | 2006-01-30 | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| PCT/FR2007/000170 WO2007085750A1 (fr) | 2006-01-30 | 2007-01-30 | Nouveaux composes pyridinylaminoalkylene- et pyridinyloxyalkylene- cyclopropanamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090523T1 true HRP20090523T1 (hr) | 2009-11-30 |
Family
ID=37102591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090523T HRP20090523T1 (hr) | 2006-01-30 | 2009-09-29 | Novi piridinilaminoalkilen i piridiniloksialkilen ciklopropanamini, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20100317698A1 (de) |
| EP (1) | EP1979321B9 (de) |
| JP (1) | JP2009525311A (de) |
| KR (1) | KR101050910B1 (de) |
| CN (1) | CN101374814B (de) |
| AR (1) | AR059221A1 (de) |
| AT (1) | ATE437857T1 (de) |
| AU (1) | AU2007209235B2 (de) |
| BR (1) | BRPI0710443A2 (de) |
| CA (1) | CA2640482C (de) |
| CY (1) | CY1109477T1 (de) |
| DE (1) | DE602007001779D1 (de) |
| DK (1) | DK1979321T3 (de) |
| EA (1) | EA015227B1 (de) |
| ES (1) | ES2330899T3 (de) |
| FR (1) | FR2896800B1 (de) |
| GE (1) | GEP20105090B (de) |
| HK (1) | HK1126190A1 (de) |
| HR (1) | HRP20090523T1 (de) |
| MA (1) | MA30222B1 (de) |
| MY (1) | MY149068A (de) |
| NO (1) | NO20083753L (de) |
| PL (1) | PL1979321T3 (de) |
| PT (1) | PT1979321E (de) |
| RS (1) | RS51065B (de) |
| SI (1) | SI1979321T1 (de) |
| UA (1) | UA88116C2 (de) |
| WO (1) | WO2007085750A1 (de) |
| ZA (1) | ZA200806399B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102216289A (zh) * | 2008-10-14 | 2011-10-12 | 塞扣吉尼克斯公司 | 烟碱乙酰胆碱受体配体及其用途 |
| US8975261B2 (en) | 2011-05-24 | 2015-03-10 | Merck Sharp & Dohme Corp. | Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors |
| SG10202008486SA (en) | 2014-09-05 | 2020-09-29 | Celgene Quanticel Research Inc | Inhibitors of lysine specific demethylase-1 |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
| CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5326100A (en) * | 1999-06-07 | 2000-12-28 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| JP2001261652A (ja) * | 2000-03-21 | 2001-09-26 | Suntory Ltd | 二置換イミノヘテロサイクリック化合物 |
| FR2810664B1 (fr) * | 2000-06-27 | 2004-12-24 | Adir | Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| FR2889188B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent |
| FR2889187B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2006
- 2006-01-30 FR FR0600784A patent/FR2896800B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-29 AR ARP070100362A patent/AR059221A1/es unknown
- 2007-01-30 DE DE602007001779T patent/DE602007001779D1/de active Active
- 2007-01-30 GE GEAP200710875A patent/GEP20105090B/en unknown
- 2007-01-30 CA CA2640482A patent/CA2640482C/fr not_active Expired - Fee Related
- 2007-01-30 EP EP07730888A patent/EP1979321B9/de active Active
- 2007-01-30 UA UAA200810613A patent/UA88116C2/ru unknown
- 2007-01-30 AT AT07730888T patent/ATE437857T1/de active
- 2007-01-30 ZA ZA200806399A patent/ZA200806399B/xx unknown
- 2007-01-30 MY MYPI20082681A patent/MY149068A/en unknown
- 2007-01-30 PL PL07730888T patent/PL1979321T3/pl unknown
- 2007-01-30 EA EA200801681A patent/EA015227B1/ru not_active IP Right Cessation
- 2007-01-30 US US12/223,311 patent/US20100317698A1/en not_active Abandoned
- 2007-01-30 AU AU2007209235A patent/AU2007209235B2/en not_active Ceased
- 2007-01-30 WO PCT/FR2007/000170 patent/WO2007085750A1/fr active Application Filing
- 2007-01-30 JP JP2008552845A patent/JP2009525311A/ja not_active Withdrawn
- 2007-01-30 PT PT07730888T patent/PT1979321E/pt unknown
- 2007-01-30 ES ES07730888T patent/ES2330899T3/es active Active
- 2007-01-30 CN CN2007800039160A patent/CN101374814B/zh not_active Expired - Fee Related
- 2007-01-30 RS RSP-2009/0450A patent/RS51065B/sr unknown
- 2007-01-30 BR BRPI0710443-0A patent/BRPI0710443A2/pt not_active IP Right Cessation
- 2007-01-30 SI SI200730068T patent/SI1979321T1/sl unknown
- 2007-01-30 KR KR1020087021424A patent/KR101050910B1/ko not_active IP Right Cessation
- 2007-01-30 DK DK07730888T patent/DK1979321T3/da active
-
2008
- 2008-08-19 MA MA31181A patent/MA30222B1/fr unknown
- 2008-09-01 NO NO20083753A patent/NO20083753L/no not_active Application Discontinuation
-
2009
- 2009-05-11 HK HK09104298.2A patent/HK1126190A1/xx not_active IP Right Cessation
- 2009-09-29 HR HR20090523T patent/HRP20090523T1/hr unknown
- 2009-10-07 CY CY20091101033T patent/CY1109477T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2697665C1 (ru) | Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их | |
| HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP6884701B2 (ja) | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 | |
| JP2004518763A5 (de) | ||
| HRP20090523T1 (hr) | Novi piridinilaminoalkilen i piridiniloksialkilen ciklopropanamini, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| JP2018505898A5 (de) | ||
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
| JP2015516429A5 (de) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| RU2005128775A (ru) | Производные пиперидинбензолсульфамида | |
| CA2941716A1 (en) | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) | |
| BR112017009701B1 (pt) | Composto e métodos de preparação de compostos | |
| RU2003105900A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью | |
| HUP0303148A2 (hu) | CB1 antagonista hatású 4,5-dihidro-1H-pirazol-származékok és e vegyületeket tartalmazó gyógyászati készítmények és eljárások az előállításukra | |
| WO2014158916A1 (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| CA2973193A1 (en) | Biguanide compound and use thereof | |
| RU2007139700A (ru) | Замещенные аминоалкил- и амидоалкилбензопиранпроизводные | |
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета | |
| JP2016531126A5 (de) | ||
| Patel et al. | Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl) phenyl] cinnamamide derivatives | |
| EP2477631A1 (de) | Substituierte phenylamin-carboxamid-analoga als negative allosterische mglur5-modulatoren sowie verfahren zu ihrer herstellung und verwendung | |
| HRP20151073T1 (hr) | Postupak sinteze i kristalni oblik 4-{3-[cis-heksahidrociklopenta[c]pirol-2(1h)-il]propoksi}benzamid hidroklorida i njegove slobodne baze kao i farmaceutski pripravci koji ih sadrže | |
| CA2522319A1 (en) | N-[(piperazinyl)hetaryl]arylsulfonamide compounds and derivatives thereof with affinity for the dopamine d3 receptor |